Most Popular
-
1
Yoon sorry for shortcomings but insists policies were right
-
2
S. Korea ‘strongly’ protests Japan’s claim over Dokdo in diplomatic bluebook
-
3
1 in 3 Koreans live alone, family types becoming diverse
-
4
US 'incredibly concerned' about suspected NK-Iran military ties
-
5
Korean won weakens amid heightened uncertainty
-
6
Korea, Japan finance chiefs vow to tame rampant FX market volatility
-
7
Seoul says will cut power to porn festival planned on Han River
-
8
Sewol victims commemorated on tragedy's 10th anniversary
-
9
Chanel, Louis Vuitton see muted growth in Korea
-
10
K-pop group's manager dismissed for setting up spycam in theater dressing room
SK Bioscience CEO says financing ready for M&As
By Kan Hyeong-wooPublished : March 31, 2022 - 15:31
SK Bioscience will look to spend “trillions of won” on aggressive mergers and acquisitions in taking the next step to become a vaccine and bio powerhouse, CEO Ahn Jae-yong said Thursday.
“We will secure more funding through the assets compiled with the (initial public offering), operating cash and additional acquisition financing,” he said in an online press conference to mark the company’s one-year anniversary of going public.
“We will use the funding on expanding the company through M&As and the COVID-19 vaccine portfolio while strengthening the overall vaccine business and increasing the infrastructure to achieve a new quantum jump.”
Referring to active investments as “inorganic growth,” the CEO said the company is currently in talks with multiple companies for strategic investments and setting up cooperative models of research and development. SK Bioscience will strengthen its vaccine competitiveness even further through M&As with global vaccine developers and in-licensing, he added.
On top of the existing business of its COVID-19 vaccine’s contract manufacturing organization, Ahn pointed out that the company will enter the market of cell and gene therapy beginning with the contract development and manufacturing organization of viral vectors.
Regarding SK Bioscience’s coronavirus vaccine candidate GBP510, the CEO expects it to be authorized by the Ministry of Food and Drug Safety within the first half of this year as estimated earlier. He noted that the result of the third and last phase of the clinical trials will be announced before the end of April. SK Bioscience previously inked a pre-contract deal with the Korean government for 10 million doses of the vaccine worth of 200 billion won ($165 million).
Besides developing GBP510, Ahn revealed that the company will soon showcase a nasal spray that uses protein-targeting technology.
“If you use the nasal spray in your nose, it will help you block the coronavirus infection for the next one to 10 days,” he said.
The CEO also highlighted that the company is in talks with various countries and international firms in a bid to expand its global footprint. He said SK Bioscience will later announce plans on setting up production footholds in the Middle East and Southeast Asia.
“We will secure more funding through the assets compiled with the (initial public offering), operating cash and additional acquisition financing,” he said in an online press conference to mark the company’s one-year anniversary of going public.
“We will use the funding on expanding the company through M&As and the COVID-19 vaccine portfolio while strengthening the overall vaccine business and increasing the infrastructure to achieve a new quantum jump.”
Referring to active investments as “inorganic growth,” the CEO said the company is currently in talks with multiple companies for strategic investments and setting up cooperative models of research and development. SK Bioscience will strengthen its vaccine competitiveness even further through M&As with global vaccine developers and in-licensing, he added.
On top of the existing business of its COVID-19 vaccine’s contract manufacturing organization, Ahn pointed out that the company will enter the market of cell and gene therapy beginning with the contract development and manufacturing organization of viral vectors.
Regarding SK Bioscience’s coronavirus vaccine candidate GBP510, the CEO expects it to be authorized by the Ministry of Food and Drug Safety within the first half of this year as estimated earlier. He noted that the result of the third and last phase of the clinical trials will be announced before the end of April. SK Bioscience previously inked a pre-contract deal with the Korean government for 10 million doses of the vaccine worth of 200 billion won ($165 million).
Besides developing GBP510, Ahn revealed that the company will soon showcase a nasal spray that uses protein-targeting technology.
“If you use the nasal spray in your nose, it will help you block the coronavirus infection for the next one to 10 days,” he said.
The CEO also highlighted that the company is in talks with various countries and international firms in a bid to expand its global footprint. He said SK Bioscience will later announce plans on setting up production footholds in the Middle East and Southeast Asia.
-
Articles by Kan Hyeong-woo
![[Today’s K-pop] BTS pop-up event to come to Seoul](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/04/17/20240417050734_0.jpg&u=)